N-Acetyl Selank
low riskAlso: NA Selank · Acetyl Selank · N-Acetyl-Thr-Lys-Pro-Arg-Pro-Gly-Pro
N-Acetyl Selank is an acetylated, metabolically stabilized analog of Selank, a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg). Selank was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as an anxiolytic with nootropic properties. The N-acetyl modification improves resistance to enzymatic degradation, extending half-life. N-Acetyl Selank is not independently studied; its evidence is extrapolated from Selank research, where it has been approved for clinical use in Russia.
Reported Benefits
Anxiolytic effects
Selank demonstrates anxiolytic effects in animal models and limited Russian clinical trials without the sedation, dependence, or cognitive impairment associated with benzodiazepines. N-Acetyl Selank is assumed equivalent or superior based on pharmacokinetics.
Cognitive enhancement and memory
Selank improves memory consolidation and cognitive performance in animal models. Human evidence is limited to small trials of variable quality.
Immune modulation
Selank shows immunostimulatory effects in animal models and anecdotally in human use. It modulates IL-6, interferon, and T-cell activity, though clinical significance is unclear.
Stress resilience
Animal models show reduced physiological stress responses; enkephalin upregulation may contribute to stress buffering effects.
Mechanism of Action
Selank and its analogs modulate the GABAergic system (similar to benzodiazepines but without dependence liability), upregulate BDNF and enkephalins, and influence serotonergic and dopaminergic signaling. It inhibits enkephalin-degrading enzymes (enkephalinase), prolonging endogenous opioid tone. The compound also modulates IL-6 and other cytokines, suggesting immune system activity. The N-acetyl modification increases plasma stability by protecting against aminopeptidase cleavage.
Key Clinical Studies
Zozulya et al. (2001)
Randomized, double-blind, placebo-controlled · 62
Selank reduced anxiety in patients with generalized anxiety disorder without sedation or dependence; comparable to medazepam with better cognitive profile
Kolik et al. (2014)
Controlled animal study · Animal
Selank showed anxiolytic and nootropic effects in rodent models; BDNF upregulation confirmed
Overview
N-Acetyl Selank is a stabilized derivative of Selank, a heptapeptide designed to be a safer anxiolytic alternative to benzodiazepines. Selank was approved in Russia as a prescription anxiolytic drug (Selanque) and shares structural roots with tuftsin, an endogenous tetrapeptide with immunomodulatory activity. Its appeal lies in producing anxiolytic and cognitive-enhancing effects simultaneously — a combination rarely achieved by standard anxiolytics, which typically impair cognition. The N-acetyl modification makes this analog more metabolically stable without altering the core pharmacology.
Evidence Summary
The evidence for Selank as an anxiolytic is preliminary but mechanistically credible. The GABAergic and enkephalinergic mechanisms are well-characterized, and the Russian clinical trial data supports efficacy in generalized anxiety disorder. The quality of those trials is moderate — mostly single-center, with methodological limitations typical of Russian clinical research from the 2000s. Independent replication in Western academic settings is absent. N-Acetyl Selank specifically has not been studied in human trials; all evidence is extrapolated.
Regulatory Status
N-Acetyl Selank is not approved in the US or EU. Selank itself is approved as a prescription drug in Russia. In the US, it exists as a research peptide in a regulatory gray area — not scheduled, not approved for compounding, not cleared for human use. All administration is off-label and experimental.
Most Common Use Cases
Intranasal administration is preferred for its direct CNS access. Users target anxiety reduction, stress buffering, and cognitive clarity — particularly in high-demand situations requiring both calm and focus. Often used alongside N-Acetyl Semax in a combined nootropic stack targeting the anxiolytic/cognitive balance. Typical cycle: 2–4 weeks followed by an equal break period.
✦ Sponsored
Stop Guessing About Your Health. Start Optimizing It.
Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.
Learn More →
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Mild nasal irritation (intranasal)
- •Sedation (uncommon, dose-dependent)
- •Mild lethargy or fatigue
- •Rare: vivid dreams
Contraindications
- •Pregnancy
- •Severe hepatic impairment
- •Active psychiatric conditions requiring careful medication management
Drug Interactions
- •Benzodiazepines (additive GABAergic effects — use with caution)
- •CNS depressants (alcohol, opioids — additive sedation)
- •SSRIs (theoretical serotonergic interaction — monitor)
Primary Uses
Related Peptides
Planning a protocol?
Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe N-Acetyl Selank?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →